Company record
Crossfire Oncology B.V.
- B.V.
Signals
2 on record
- EPO patentsPatent
Patent publication AU2025266872A1 by CROSSFIRE ONCOLOGY B.V.: BIFUNCTIONAL COMPOUNDS CAPABLE OF INDUCING DEGRADATION OF POLO-LIKE KINASE1.
EPO patentsRelevance21
Watch · 80% confidence
- RVO subsidiesSubsidy
Crossfire Oncology B.V. was awarded Innovatiekrediet of EUR 854,257. Project: PLK1-based Degrader Antibody Conjugate platform.
RVO subsidiesRelevance22
Watch · 72% confidence